Portal de Periódicos da CAPES

Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

2005; Elsevier BV; Volume: 239; Issue: 1 Linguagem: Inglês

10.1016/j.jns.2005.08.003

1878-5883

Hillel S. Panitch, Douglas S. Goodin, Gordon Francis, Peter Chang, Patricia K. Coyle, Paul O’Connor, David Li, Brian G. Weinshenker,

Peripheral Neuropathies and Disorders

The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif®), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex®), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing–remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44mcg sc tiw, for relapse measures and MRI activity, compared with IFN beta-1a, 30mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes.